
Inovio Pharmaceuticals, a US biotech firm, specializes in developing DNA vaccines, anti-inflammatory drugs, and animal health products.
Inovio Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of DNA medicines aimed at treating and protecting against diseases such as human papillomavirus (HPV), cancer, and infectious diseases. Utilizing its SynCon technology to optimize DNA sequences and CELLECTRA smart devices for effective delivery, Inovio focuses on creating innovative DNA vaccines and anti-inflammatory drugs. The company is based in Plymouth Meeting, Pennsylvania.
Inovio has made significant strides in the biotech industry, with notable achievements including the development of DNA-based vaccines and therapies. The company has participated in various investor conferences and reported substantial business highlights, reflecting its active engagement with the scientific and investment communities. Inovio's advancements in DNA medicine have positioned it as a key player in the fight against infectious diseases and cancer.

Innovent Biologics

Twist Bioscience

Imunon
imunon.com

Innovac Therapeutics
innovactx.com

INmune Bio
inmunebio.com

Innox
innoxpharma.com

Iovance Biotherapeutics
iovance.com

PepVax
pepvax.co

MacroGenics
macrogenics.com

Inmagene Biopharmaceuticals
inmagenebio.com

GeoVax Labs
geovax.com

AmplifyBio

Dynavax Technologies
dynavax.com

Immunome

Novavax
novavax.com
Companies similar to Inovio Pharmaceuticals include Innovent Biologics, Twist Bioscience, Imunon and Innovac Therapeutics.
Inovio Pharmaceuticals was founded in 1979.
Inovio Pharmaceuticals' headquarters is located in Plymouth Meeting, PA, US.
Inovio Pharmaceuticals' most recent funding round was for $150.5M (USD) in January 2021.
As of Jan 20, 2021, Inovio Pharmaceuticals has raised a total of $18.4B (USD).
Inovio Pharmaceuticals has 262 employees as of Feb 6, 2024.